🔗 Share this article

The Nobel Prize in Physiology or Medicine has been granted for revolutionary findings that illuminate how the body's defense network attacks harmful infections while protecting the healthy tissues.

Three esteemed researchers—from Japan Shimon Sakaguchi and American scientists Dr. Brunkow and Fred Ramsdell—share this honor.

The work identified specialized "sentinels" within the immune system that remove malfunctioning defense cells capable of harming the body.

These findings are now paving the way for innovative treatments for autoimmune diseases and malignancies.

The winners will divide a prize fund valued at 11m SEK.

Crucial Findings

"The research has been decisive for understanding how the immune system functions and the reason we don't all suffer from serious self-attack conditions," stated the head of the award panel.

The trio's research address a core question: In what way does the immune system protect us from countless invaders while keeping our own tissues unharmed?

The body's protection system uses immune cells that search for signs of infection, including pathogens and germs it has never encountered.

Such defenders utilize detectors—called recognition units—that are produced by chance in countless variations.

That provides the immune system the capacity to fight a broad range of invaders, but the randomness of the mechanism inevitably creates white blood cells that may target the host.

Security Guards of the Immune System

Scientists earlier knew that a portion of these problematic defense cells were destroyed in the immune organ—the site where immune cells develop.

The latest Nobel Prize recognizes the discovery of T-reg cells—described as the immune system's "peacekeepers"—which patrol the system to disarm any defenders that assault the body's own tissues.

We know that this mechanism fails in autoimmune diseases such as type-1 diabetes, MS, and rheumatoid arthritis.

The prize committee stated, "These discoveries have established a new field of research and accelerated the development of innovative treatments, for example for cancer and immune disorders."

In cancer, regulatory T-cells prevent the body from fighting the growth, so research are aimed at lowering their quantity.

In autoimmune diseases, trials are testing boosting regulatory T-cells so the organism is no longer under attack. A similar approach could also be useful in reducing the chances of transplanted organ failure.

Pioneering Studies

Professor Sakaguchi, of a Japanese institution, performed tests on mice that had their thymus removed, leading to self-attack conditions.

He demonstrated that injecting immune cells from healthy mice could stop the illness—implying there was a system for blocking defenders from harming the host.

Mary Brunkow, affiliated with the Institute for Systems Biology in Seattle, and Dr. Ramsdell, currently at a biotech firm in San Francisco, were investigating an genetic autoimmune disease in rodents and humans that resulted in the identification of a gene vital for how regulatory T-cells function.

"The pioneering research has uncovered how the immune system is controlled by regulatory T cells, stopping it from mistakenly attacking the body's own tissues," said a prominent physiology expert.

"The work is a remarkable example of how fundamental physiological study can have broad consequences for human health."